



BioSpectrum Ranking Survey: Rank 10: GSK India

16 September 2016 | Features | By BioSpectrum Bureau

BioSpectrum Ranking Survey: Rank 10: GSK India

GSK India

MD & VP South Asia: Annaswamy Vaidheesh

Designation:

Revenue: Rs 400 crore

GSK India's vaccines business revenue for FY2015-16 stood at over Rs 400 crore compared to Rs 440 crore in FY2014-15.

In FY2015-16, GlaxoSmithKline India's biggest milestone was its investment in building its new tablet manufacturing factory in Vemgal, Karnataka, with a whopping investment of Rs 1,000 crore.

The facility is expected to be fully operational in 2017. The factory is said to manufacture more than 8 billion tablets and 1 billion capsules in areas of gastroenterology and anti-inflammatory medicines for the Indian market.

In June last year, the company announced the appointment of Annaswamy Vaidheesh, as GSK India's VP for South Asia and MD, succeeding Dr Hasit Joshipura.

In September 2015, GSK Pharmaceuticals completed acquiring Novartis' vaccines business. In April 2016, the company launched its school sanitation project at Nashik, Maharashtra.

The company has initiated CSR partnerships addressing the entire continuum of care for newborn survival in high-burden districts of Rajasthan and Madhya Pradesh.

The fiscal year under review also saw GSK winning second rank under the title 'Most Respected Companies in India' by Business World magazine in the pharma sector.

Business Today magazine ranked it at second place under 'Best Companies to Work For' in the pharma and healthcare sector.